Shanghai Junshi Biosciences Co., Ltd. (OTCMKTS:SHJBF) Short Interest Update

Shanghai Junshi Biosciences Co., Ltd. (OTCMKTS:SHJBF) saw a large decline in short interest in September. As of September 15th, there was short interest totaling 1,000 shares, a decline of 98.4% from the August 31st total of 63,000 shares. Based on an average trading volume of 0 shares, the days-to-cover ratio is currently ∞ days.

Shanghai Junshi Biosciences Stock Performance

Shanghai Junshi Biosciences stock opened at C$3.35 on Friday. Shanghai Junshi Biosciences has a 12 month low of C$2.99 and a 12 month high of C$4.23. The company’s fifty day simple moving average is C$3.35 and its 200-day simple moving average is C$3.24.

About Shanghai Junshi Biosciences

Shanghai Junshi Biosciences Co, Ltd. is a Shanghai-based biopharmaceutical company dedicated to the research, development and commercialization of monoclonal antibody therapeutics. Since its founding in 2012 as a spin-off from the Shanghai Institute of Pharmaceutical Industry, Junshi has focused on leveraging cutting-edge antibody engineering platforms to develop innovative treatments for oncology, autoimmune conditions, infectious diseases and metabolic disorders. The company’s lead product, toripalimab (Tuoyi), was among the first anti-PD-1 antibodies approved by Chinese regulatory authorities for the treatment of advanced melanoma and nasopharyngeal carcinoma, demonstrating Junshi’s capability to translate research into commercially available immuno-oncology therapies.

Junshi’s pipeline encompasses a diversified portfolio of antibody-based candidates targeting immune checkpoints, cytokines and other disease-associated proteins.